Scientists have known for decades that eating 25% less slows aging. A new study finally found the specific protein responsible, and blocking it works without dieting at all.
The evidence that calorie restriction slows aging has been accumulating since the 1930s, when researchers first noticed that underfed laboratory rats lived significantly longer than their normally fed counterparts. In the decades since, the finding has been replicated in yeast, worms, flies, mice, and rats with extraordinary consistency. Reduce calorie intake without causing malnutrition, and something in the biology of aging slows down. The effect is real, large, and reproducible across species separated by hundreds of millions of years of evolution.
The human evidence has been harder to obtain, simply because running a controlled calorie restriction trial in people for years is logistically and ethically complex. The most rigorous attempt, the CALERIE trial sponsored by the National Institute on Aging, enrolled 220 healthy adults and asked half of them to cut their daily calorie intake by 25 percent for two years while maintaining nutritional adequacy. The calorie-restricted participants showed improvements in metabolic health, reduced inflammation, improved immune function, and biological aging markers that moved in the direction of slower aging.
The problem is that virtually nobody outside a clinical trial can sustain 25 percent calorie reduction indefinitely. The intervention works. The practicality is essentially zero.
A new study published in Nature Aging, led by Vishwa Deep Dixit at Yale School of Medicine and drawing on blood samples from the CALERIE trial participants, has identified what may be the central biological mechanism through which calorie restriction produces its anti-aging effects. And having identified it, the researchers have shown in mice that targeting the same mechanism pharmacologically, without any dietary restriction, produces comparable benefits.
What changed in the blood of people eating less
The CALERIE trial provided the research team with a rare resource: blood samples collected from people before, during, and after two years of sustained calorie restriction, compared against a control group eating normally. Rather than measuring only the usual markers of metabolic health, the Yale team took a broader approach, analyzing the exoproteome, the full collection of proteins secreted by cells into the bloodstream, to look for proteins that changed most significantly with calorie restriction.
One protein stood out above all others: complement component 3, universally abbreviated as C3.
C3 is a central hub of the complement system, an ancient branch of the innate immune system that has been conserved across virtually all multicellular life. Its primary function is to tag pathogens and damaged cells for destruction by other immune components. It is one of the most abundant proteins in human blood, present at concentrations several times higher than most other immune proteins.
What has become increasingly apparent in aging research is that C3 and the complement system more broadly also play a major role in driving inflammaging, the chronic low-grade inflammatory state that accumulates with age and that underlies the biology of virtually every major age-related disease, including cardiovascular disease, type 2 diabetes, neurodegeneration, and cancer. As complement activation increases with age, the background level of immune activation rises with it, producing a persistent inflammatory signal that gradually erodes tissue function across the body.
In the calorie-restricted CALERIE participants, C3 levels dropped substantially compared to the control group. Markers of complement activation fell. The chronic inflammatory signal that characterizes biological aging was measurably lower.
“We find that moderate calorie restriction in humans results in reduction of a complement protein C3 in circulation,” Dixit said. “Complement is an ancient innate immune system, and C3 is the central node of it. It’s like the internet hub: everything converges there.”
What happened when C3 was blocked in mice without any diet change
The human data established the correlation: calorie restriction reduces C3. But correlation does not establish causation. The critical question was whether C3 reduction was a cause of the anti-aging benefits or simply a downstream marker of some other change that calorie restriction was producing.
To test this, the researchers moved to mouse studies. They used aged mice and administered a compound that blocks C3 activity without altering the animals’ food intake. The mice continued eating their normal diet. The only change was the pharmacological suppression of C3.
The results closely replicated the profile seen in the calorie-restricted mice and humans. Inflammaging markers fell. Metabolic function improved. Thymic function, one of the most sensitive measures of immune system vitality with age, was substantially better preserved in the C3-blocked mice than in untreated controls of the same age.
The thymus is particularly significant in this context. It is the organ responsible for producing and maturing T cells, the adaptive immune system’s primary soldiers. The thymus undergoes a process called involution beginning in early adulthood, progressively shrinking and losing function as the body ages. By old age, thymic function is severely diminished, which is one of the primary reasons older adults respond less robustly to new infections and vaccines. Prior CALERIE analyses had already shown that calorie restriction partially preserved thymic function. The new study showed that blocking C3 reproduced that preservation in aged mice without dietary change.
“It was remarkable to see that just by targeting this complement protein, we were able to replicate some of the key benefits of calorie restriction in aged mice,” said Manish Mishra, the study’s first author.
Why this finding changes the practical landscape
The history of calorie restriction research is partly a history of frustration. The biology is compelling. The human translatability is poor. Most people cannot eat 25 percent less for the rest of their lives, and the field has spent decades looking for interventions that capture the same mechanism without requiring permanent dietary deprivation.
Several candidates have emerged over the years. Rapamycin, which inhibits a cellular pathway called mTOR that senses nutrient availability, produces some calorie-restriction-like effects in mice and has attracted intense interest in longevity medicine. Metformin, the diabetes drug, activates AMPK and produces metabolic effects that partially overlap with calorie restriction. Intermittent fasting and time-restricted eating approximate some features of the calorie-restricted state for limited periods.
What distinguishes the C3 finding is its specificity. Rather than targeting a broad metabolic pathway that intersects with calorie restriction, the research identified a specific secreted protein that changes in calorie-restricted humans and that, when targeted directly, reproduces key benefits in aged animals. C3 inhibitors already exist in clinical medicine, approved for rare immune disorders in which complement overactivation causes severe tissue damage.
Whether those existing drugs, or purpose-designed C3 modulators, could safely and effectively be used in healthy aging adults to replicate the anti-inflammatory benefits of calorie restriction is a clinical question that requires human trials. The mouse data establish the proof of concept. The human CALERIE data establish that the mechanism is present and operative in people. The distance between those two facts and a safe, approved anti-aging intervention is still years of clinical development.
What the study does not claim
The researchers are careful about the scope of their conclusions. Blocking C3 in aged mice improved inflammatory profiles and immune function. It did not replicate every measured effect of calorie restriction, and the study did not demonstrate extended lifespan in the pharmacological group, a metric that would require longer-term studies than were conducted.
The CALERIE trial was conducted in healthy, non-obese adults with no major metabolic disease. Whether the same C3 reduction and its downstream effects operate in people with obesity, metabolic syndrome, or established chronic disease is unknown.
The complement system also plays essential protective functions, and suppressing C3 is not without risk. Current clinical uses of C3 inhibition involve people with rare, severe complement-driven disorders where the benefit clearly outweighs the risk of reduced complement activity. Using similar approaches in healthy people for anti-aging purposes requires careful safety evaluation in clinical trials before any recommendation would be appropriate.
What the study establishes is the identification of a specific immunometabolic checkpoint that mediates a significant portion of calorie restriction’s anti-aging effect in humans, and the demonstration that targeting it pharmacologically in animals reproduces those benefits without dietary change. It is, in the researchers’ framing, proof of concept that the hunger may not be the point.
“The goal now is to understand whether we can harness this complement checkpoint therapeutically to promote healthspan in humans,” Dixit said, “without requiring them to restrict their calories for life.”
The study, “Exoproteome of calorie-restricted humans identifies complement deactivation as an immunometabolic checkpoint reducing inflammaging”, was authored by Manish Mishra, Hee-Hoon Kim, Yun-Hee Youm, and colleagues at Yale School of Medicine and collaborating institutions, and published August 2026 in Nature Aging.
Source: Yale School of Medicine. DOI: 10.1038/s43587-026-01107-0
